Form 4: CEO Goldsmith Exercises Options, Sells RVMD Shares

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and sold a significant number of shares, primarily through a pre-arranged 10b5-1 trading plan.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer, and Director of Revolution Medicines, Inc. (RVMD), reported multiple transactions.
• On March 1, 2026, Goldsmith was granted 57,100 shares of common stock at a price of $0 and 128,600 stock options with an exercise price of $102.02, which will vest monthly over four years from the vesting commencement date.
• On March 2, 2026, Goldsmith exercised 30,000 stock options with an exercise price of $4.09.
• Concurrently, Goldsmith directly sold 30,000 shares of common stock at weighted average prices ranging from $98.1708 to $102.1994.
• Additionally, trusts associated with Goldsmith (Jonathan Goldsmith Revocable Trust and Rebecca Goldsmith Revocable Trust) sold a combined 6,000 shares at weighted average prices ranging from $98.29 to $102.08.
• All sales on March 2, 2026, were executed under a Rule 10b5-1 trading plan adopted on December 19, 2024.
• Following these transactions, Goldsmith directly beneficially owns 289,569 shares (including 225,863 restricted stock units) and indirectly owns 594,060 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, 64,424 shares through the Jonathan Goldsmith Revocable Trust, and 64,424 shares through the Rebecca Goldsmith Revocable Trust.
• Goldsmith also holds 47,708 exercisable stock options and 128,600 newly granted stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction involving both new equity grants and planned sales for liquidity, typical for an executive. The 10b5-1 plan mitigates negative sentiment from the sales.

Positives

• The grant of 57,100 common shares at $0 to the CEO indicates continued equity incentive and alignment with company performance.
• The grant of 128,600 stock options to the CEO, vesting over four years, further aligns management incentives with long-term company performance.
• The sales were conducted under a pre-arranged 10b5-1 trading plan, which suggests a planned liquidity event rather than an immediate reaction to new, potentially negative, information.

Negatives

• Significant insider selling of 36,000 shares by the CEO and associated trusts, which could be perceived negatively by some investors.
• The sales occurred at prices ranging from approximately $98 to $102, which are substantially higher than the $4.09 exercise price for the options, indicating the CEO is realizing significant profits.

Risks

• Potential negative market perception due to significant insider selling, even if pre-planned, which could put downward pressure on the stock price.

Future Outlook

The vesting schedule for the newly granted 128,600 stock options indicates a long-term incentive structure, with shares vesting monthly over four years from March 1, 2026, contingent on continued service.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common for executives managing personal finances or diversifying portfolios. The use of a 10b5-1 plan indicates a pre-scheduled transaction, which is generally viewed more favorably than unscheduled sales, as it suggests the decision was made without reliance on material non-public information. In the biotechnology sector, executive compensation often includes significant equity components, leading to periodic exercises and sales for liquidity.

Comparison to Industry Standards

• StockSavvy.ai observes that the exercise of deeply in-the-money options (exercise price $4.09 vs. sale prices ~$100) followed by immediate sales is a standard practice for executives to realize value from their compensation.
• The grant of new options and shares at $0 is also a common incentive mechanism for executive compensation.
• Compared to industry peers, the scale of this transaction is typical for a CEO of a company of Revolution Medicines' size, reflecting a balance between long-term equity alignment and personal financial planning.

Related Party Transactions

• Transfer of 24,010 shares to the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
• Sales of shares by Jonathan Goldsmith Revocable Trust and Rebecca Goldsmith Revocable Trust, which are associated with the reporting person.

Stakeholder Impact

• Shareholders: May perceive the insider sales as a signal, though the 10b5-1 plan mitigates concerns. The new grants align CEO interests with long-term shareholder value.

Next Steps

• Continued vesting of 128,600 stock options monthly over four years from March 1, 2026, subject to continued service.

Key Dates

Recommendation

The filing details routine insider transactions, including the exercise of options and subsequent sales under a pre-arranged 10b5-1 plan, alongside new equity grants. While sales by a CEO can sometimes be a negative signal, the pre-planned nature and simultaneous new grants suggest a standard compensation and liquidity management strategy rather than a bearish outlook on the company. Therefore, the filing itself does not provide a strong catalyst for a 'buy' or 'sell' recommendation, warranting a 'hold' based solely on this information.

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Options, Share Sale, CEO, Mark A. Goldsmith, 10b5-1 Plan, Biotechnology, Pharmaceuticals